<DOC>
	<DOCNO>NCT00914940</DOCNO>
	<brief_summary>RATIONALE : Allogeneic hematopoietic stem cell transplant ( HSCT ) treatment cure acute leukemia myelodysplasia . After give patient chemotherapy total body irradiation stop growth cancer remove patient 's diseased bone marrow , healthy stem cell donor infused patient replace patient 's bone marrow make red white blood cell platelet . Unfortunately HSCT often complicate 'graft versus host disease ' ( GVHD ) transplant cell donor make immune response body 's normal cell cause tissue damage severe symptom . Removing subset donor T cell , call 'naive T cell ' , transplant may reduce frequency intensity GVHD . PURPOSE : This phase II trial determine whether removal naive T cell donor cell decrease rate severity graft-vs-host disease preserve specific immunity infection patient acute leukemia advance myelodysplastic syndrome .</brief_summary>
	<brief_title>Selective Depletion CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts Prevention GVHD</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate probability grade II-IV acute graft-vs-host disease ( GVHD ) patient acute leukemia advance myelodysplastic syndrome treat CD45RA+ T-cell-depleted allogeneic peripheral blood stem cell transplantation compare relevant historical experience . - Estimate probability graft failure patient . Secondary - Evaluate immune reconstitution pathogen-specific T-cell reconstitution patient . - Estimate probability transplant-related mortality day 100 patient . - Estimate probability relapse patient . - Estimate probability severity chronic GVHD patient . OUTLINE : This multicenter study . - Myeloablative conditioning regimen : Patients undergo total body irradiation twice daily 4 day ( Days -10 -7 ) Patients also receive thiotepa IV 4 hour 2 day ( Days -6 -5 ) fludarabine phosphate IV 30 minute 5 day ( Days -6 -2 . ) - Transplantation : Patients receive CD34+ enrich allogeneic peripheral blood stem cell ( PBSC ) product follow CD45RA+ T-cell-depleted allogeneic PBSC product day 0 . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive Tacrolimus per cohort 1 . If rate grade II-IV acute GVHD first 35 patient significantly reduce ( compare historical control ) , subsequent patient enrol cohort 2 . - Cohort 1 : Patients receive tacrolimus IV continuously orally twice daily begin day -1 continue day 50 , follow standard taper absence grade II-IV acute GVHD . - Cohort 2 : Patients receive tacrolimus IV continuously orally twice daily begin day -1 continue day 30 , follow rapid taper absence grade II-IV acute GVHD . Patients follow actively least 1 year post transplant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute lymphocytic leukemia ( ALL ) acute myeloid leukemia ( AML ) first subsequent remission ALL AML relapse primary refractory ALL AML circulate blast count â‰¤ 10,000/mm^3 Refractory anemia excess blast ( RAEB ) ( RAEB1 RAEB2 ) patient receive induction chemotherapy within past 60 day Appropriate candidate allogeneic hematopoietic stem cell transplantation ( HSCT ) No CNS involvement refractory intrathecal chemotherapy and/or standard cranialspinal radiotherapy PATIENT CHARACTERISTICS : Age 1455 Creatinine &lt; 1.5 mg/dL Cardiac ejection fraction &gt; 45 % DLCO correct &gt; 60 % predict Total bilirubin &lt; 2 time upper limit normal ( ULN ) ( unless attribute Gilbert syndrome ) AST ALT &lt; 2 time ULN Not pregnant nursing Fertile patient must use effective contraception 12 month transplantation HIV negative No coexisting disease ( leukemia RAEB ) would limit life expectancy &lt; 3 month No uncontrolled infection , opinion consult infectious disease physician , would contraindicate myeloablative HSCT No medical condition would contraindicate HSCT No known hypersensitivity tacrolimus PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior HSCT No concurrent participation experimental study prevention graftvshost disease DONOR CHARACTERISTICS : Genotypic phenotypic HLAidentical related donor Able donate peripheral blood stem cell Age &gt; 14 year Applicable male patient : No female donor previously give birth male child pregnancy beyond first trim miscarriage termination pregnancy nurse No donor receive blood transfusion No CD45 Mutation aberrant CD45RA isoform expression</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>